Drug intelligence / Profile preview

Bifidobacterium longum NSP002

Development stage: Preclinical
Lead developer: Nanchang University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum NSP002 is a specific bacterial strain identified as a dominant gut commensal that is significantly enriched by dietary fiber, specifically low-esterified pectin. It is being investigated as a live biotherapeutic product (LBP) for the treatment of inflammatory bowel diseases, such as ulcerative colitis. Research conducted at Nanchang University indicates that NSP002, particularly when administered as part of a microbial consortium, exerts a protective effect against colitis by remodeling the gut microbiome, increasing the production of propionic acid, and modulating intestinal homeostasis. Mechanistically, it has been shown to activate the PI3K/calcium signaling pathway and influence systemic metabolic reprogramming, specifically affecting phenylalanine metabolism.

Targets

ORAI2 (Orai calcium release-activated calcium modulator 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on Bifidobacterium longum NSP002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium longum NSP002.

Explore the full profile